Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.

Original title: “United rises on IPF data; Biogen scores positive lupus data and an approval”

design of a phase ii randomised double blind placebo controlled dose finding trial of bi 1819479 in patients with idiopathic pulmonary fibrosis

Original title: “Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis.”

cocos ipf core outcome set for idiopathic pulmonary fibrosis progressive pulmonary fibrosis care a mixed method multi perspective approach

Original title: “The COCOS-IPF core outcome set for idiopathic pulmonary fibrosis/progressive pulmonary fibrosis care: a mixed-method multi-perspective approach.”

bexotegrast for treatment of idiopathic pulmonary fibrosis beacon ipf study protocol for a multinational phase 2b 3 double blind randomised multicentre controlled trial

Original title: “Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.”

economic burden of idiopathic pulmonary fibrosis updated evidence on costs and resource use

Original title: “Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use.”

nerandomilast in idiopathic pulmonary fibrosis data from the whole follow up period of the fibroneer ipf trial

Original title: “Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.”

The two offerings capped off the busiest week for new biotech stock issuances in a year. The European biotech has a second drug in human testing it believes could be useful as a standalone treatment or combination agent with other therapies for idiopathic pulmonary fibrosis. Data from an early-stage study could come in the second half of 2026. Prior to its IPO, Agomab raised nearly $300 million in venture funding. Boston Business Journal Biotech leaders warn millionaires tax is driving investors out of Massachusetts View all ... Making the Specialty Medication Journey Easier—for Patients and Providers Webinar - on demand • Provided by DrFirst · Developing an Array of Diverse Vaccine Platforms Webinar - on demand • Provided by BioPharma Dive's studioID; Sponsored content by Novavax in partnership with studioID Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday, ending a week that has seen investors pour more than $1 billion into the coffers of newly public biotechnology companies. SpyGlass, which is making long-acting therapies for ocular diseases, raised $150 million, sold nearly 9.4 million shares for $16 apiece. Metsera, which closed 2025’s second-largest IPO, was acquired by Pfizer in a $10 billion deal. A handful of other companies, among them artificial intelligence-focused Generate Biomedicines, have recently joined the queue as well. Agomab, headquartered in Belgium, has three drugs in development for immunological diseases.

Original title: “Agomab, SpyGlass bank a combined $350M in biotech IPOs | BioPharma Dive”